scholarly journals Outcome of Wilms tumor patients with bone metastasis enrolled on National Wilms Tumor Studies 1-5: A report from the Children's Oncology Group

2018 ◽  
Vol 66 (1) ◽  
pp. e27430 ◽  
Author(s):  
Douglas S. M. Iaboni ◽  
Yueh-Yun Chi ◽  
Yeonil Kim ◽  
Jeffrey S. Dome ◽  
Conrad V. Fernandez
Keyword(s):  
Bone Metastasis ◽  
Wilms Tumor ◽  
Oncology Group ◽  
Tumor Patients ◽  
Tumor Studies

scholarly journals Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor

2021 ◽  
Vol 19 (8) ◽  
pp. 978-985
Author(s):  
Jeffrey S. Dome ◽  
Elizabeth A. Mullen ◽  
David B. Dix ◽  
Eric J. Gratias ◽  
Peter F. Ehrlich ◽  
...  
Keyword(s):  
Clinical Practice ◽  
First Generation ◽  
Renal Tumor ◽  
Wilms Tumor ◽  
Lung Nodule ◽  
Significant Proportion ◽  
Oncology Group ◽  
Treatment Regimens ◽  
Tumor Studies

Refinements in surgery, radiation therapy, and chemotherapy since the mid-20th century have resulted in a survival rate exceeding 90% for patients with Wilms tumor (WT). Although this figure is remarkable, a significant proportion of patients continue to have event-free survival (EFS) estimates of <75%, and nearly 25% of survivors experience severe chronic medical conditions. The first-generation Children’s Oncology Group (COG) renal tumor trials (AREN ‘0’), which opened to enrollment in 2006, focused on augmenting treatment regimens for WT subgroups with predicted EFS <75% to 80%, including those with the adverse prognostic marker of combined loss of heterozygosity (LOH) at chromosomes 1p/16q, pulmonary metastasis with incomplete lung nodule response after 6 weeks of chemotherapy, bilateral disease, and anaplastic histology. Conversely, therapy was reduced for patient subgroups with good outcomes and potential for long-term toxicity, such as those with lung metastasis with complete lung nodule response after 6 weeks of chemotherapy. This article summarizes the key findings of the first-generation COG renal tumor studies and their implications for clinical practice.

Breast-feeding and Wilms Tumor: A Report from the Children’s Oncology Group

2006 ◽  
Vol 17 (5) ◽  
pp. 687-693 ◽  
Author(s):  
Stephanie Saddlemire ◽  
Andrew F. Olshan ◽  
Julie L. Daniels ◽  
Norman E. Breslow ◽  
Greta R. Bunin ◽  
...  
Keyword(s):  
Breast Feeding ◽  
Wilms Tumor ◽  
Oncology Group

scholarly journals Barriers to the Enrollment of Children in the Childrenʼs Oncology Group Study of Very Low Risk Wilms Tumor

2011 ◽  
Vol 33 (7) ◽  
pp. 521-523 ◽  
Author(s):  
Conrad V. Fernandez ◽  
Ning Li ◽  
Elizabeth A. Mullen ◽  
Paul E. Grundy ◽  
Elizabeth J. Perman ◽  
...  
Keyword(s):  
Wilms Tumor ◽  
Low Risk ◽  
Oncology Group ◽  
Oncology Group Study

Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study.

1993 ◽  
Vol 11 (1) ◽  
pp. 91-95 ◽  
Author(s):  
D M Green ◽  
N E Breslow ◽  
J B Beckwith ◽  
J Takashima ◽  
P Kelalis ◽  
...  
Keyword(s):  
Wilms Tumor ◽  
Stage I ◽  
P Value ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Treatment Regimens ◽  
Survival Percentage ◽  
Favorable Histology ◽  
Specimen Weight ◽  
Tumor Studies

PURPOSE Retrospective analyses were performed to determine the effect of tumor weight and therapy modifications on outcome in patients less than 2 years of age with stage I favorable-histology Wilms' tumors. PATIENTS AND METHODS The 4-year relapse-free and overall survival percentages for patients randomized to different treatment regimens in National Wilms' Tumor Studies (NWTS)-1, -2, and -3 were calculated and compared. RESULTS The 4-year relapse-free survival percentages of patients whose specimen weight was less than 550 g were found to be 89.1% on NWTS-1, 96.0% on NWTS-2, and 93.2% on NWTS-3. There was no evidence that the relapse-free survival of these patients had improved over time (P value for trend = .99). The 4-year relapse-free survival percentage for similar age and stage patients whose specimen weight was 550 g or greater was significantly poorer than that of patients with smaller tumors (P = .02). CONCLUSION Changes in the NWTS treatment regimens over a period of more than 20 years have not improved on the excellent prognosis of patients who are less than 2 years of age at diagnosis and who have a stage I, favorable-histology Wilms' tumor with specimen weight less than 550 g. These data could be used as the basis for a future trial in which a subgroup of such patients is treated with nephrectomy only.

scholarly journals Predicting Relapse in Favorable Histology Wilms Tumor Using Gene Expression Analysis: A Report from the Renal Tumor Committee of the Children's Oncology Group

2009 ◽  
Vol 15 (5) ◽  
pp. 1770-1778 ◽  
Author(s):  
Chiang-Ching Huang ◽  
Samantha Gadd ◽  
Norman Breslow ◽  
Colleen Cutcliffe ◽  
Simone T. Sredni ◽  
...  
Keyword(s):  
Gene Expression ◽  
Expression Analysis ◽  
Gene Expression Analysis ◽  
Renal Tumor ◽  
Wilms Tumor ◽  
Oncology Group ◽  
Favorable Histology

Renin-induced hypertension in Wilms tumor patients

2007 ◽  
Vol 48 (5) ◽  
pp. 500-503 ◽  
Author(s):  
M.H. Maas ◽  
K. Cransberg ◽  
M. van Grotel ◽  
R. Pieters ◽  
M.M. van den Heuvel-Eibrink
Keyword(s):  
Wilms Tumor ◽  
Tumor Patients ◽  
Induced Hypertension

Non-11p Constitutional Chromosome Abnormalities in Wilms' Tumor Patients

1995 ◽  
Vol 24 (5) ◽  
pp. 305-309 ◽  
Author(s):  
Jane M. Olson ◽  
Anne Hamilton ◽  
Norman E. Breslow
Keyword(s):  
Wilms Tumor ◽  
Chromosome Abnormalities ◽  
Tumor Patients

EP-1357: Dosimetric assessment of IMRT in total abdominal irradiation in Wilms tumor patients

2014 ◽  
Vol 111 ◽  
pp. S107
Author(s):  
M. Ramos Albiac ◽  
D. Mosquera ◽  
M. Hermida-López ◽  
J. Giralt
Keyword(s):  
Wilms Tumor ◽  
Tumor Patients ◽  
Dosimetric Assessment ◽  
Abdominal Irradiation
Sign in / Sign up

Export Citation Format

Share Document